"But at least half those new products will be specialty and biologically derived targeted therapies for cancer, autoimmune diseases, Alzheimer???s and other conditions, predicted Michael Kleinrock, head of research for IMS. ???We???re not talking about a return to the late ???90s or the early 2000s, when there were 40 or more [new molecular entities] some years, and they???re not all mega-blockbust" . . . . .